Document is current
Any future updates will be listed below
-
Authors
Olszewski, Michael https://orcid.org/0009-0007-7256-8323
Bjurström, Karl https://orcid.org/0009-0004-0832-025X
Lingman, Markus https://orcid.org/0000-0002-4068-0341
Henrohn, Dan https://orcid.org/0000-0001-9514-1153
Shojaiyan, Poyan https://orcid.org/0009-0004-1861-1851
Garell, Magnus https://orcid.org/0009-0003-2850-2221
Agvall, Björn https://orcid.org/0000-0002-3956-6103
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 22 March 2025
Accepted: 19 August 2025
First Online: 26 September 2025
Declarations
:
: Poyan Shojaiyan (PS) and Dan Henrohn (DH) are employed by AstraZeneca (AZ). The remaining authors declare that there is no conflict of interest.
: The Swedish Ethical Review Board at the Umeå Department of Medicine. with registration number 2021-04609. Granted approval for this study. Informed consent was waived. and this study procedure was authorized by the Swedish Ethical Review Board. Umeå Department of Medicine. All methodologies employed in this research adhered strictly to the applicable guidelines and regulations.
: Not applicable.
